Pfizer Inc. ($PFE) Stock Forecast: Down 2.2% Today

What is Pfizer Inc.?

Pfizer Inc. (PFE) is a multinational pharmaceutical corporation known for its innovative drugs and acquisitions in the healthcare industry. Today, the stock experienced a strong bearish movement in the market.

Why is Pfizer Inc. going down?

PFE stock is down 2.2% on Nov 10, 2025 15:35

• The bearish movement in Pfizer's stock could be attributed to the uncertainty surrounding the fierce bidding war with Novo Nordisk over the acquisition of Metsera, Inc., a significant deal worth $10 billion. The market might be reacting negatively to the potential financial implications and risks associated with this high-stakes competition.
• Additionally, Trump's Most Favored Nation (MFN) policy aimed at reducing U.S. drug prices could be adding pressure on Pfizer and other pharmaceutical companies, leading to concerns about future revenue streams and profitability.
• The court's decision to deny Pfizer's request for a temporary restraining order to block Novo Nordisk's bid for Metsera might have further fueled investor uncertainty and contributed to the bearish sentiment surrounding Pfizer's stock.
• Overall, the combination of the bidding war, drug pricing concerns, and legal setbacks could have collectively influenced the bearish market movement for Pfizer today. Investors are likely closely monitoring the developments in these ongoing battles and policy changes to assess the company's future performance.

PFE Price Chart

PFE Technical Analysis

PFE News

Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?

With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?

https://www.zacks.com/stock/news/2788262/does-trumps-mfn-policy-put-pharma-etfs-in-the-crosshairs

Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance - Metsera ( NASDAQ:MTSR ) , Eli Lilly ( NYSE:LLY )

Pfizer Inc. ( NYSE:PFE ) secured a $10 billion deal to acquire obesity drug developer Metsera, Inc. ( NASDAQ:MTSR ) , beating out Novo Nordisk A/S ( NYSE:NVO ) after a heated bidding war that captivated Wall Street.

https://www.benzinga.com/m-a/25/11/48738704/pfizer-clinches-10-billion-deal-to-buy-obesity-drug-maker-metsera-outbidding-novo-nordisk-in-fierce-battle-fo

Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call

Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark U.S. drug pricing deal.

https://www.zacks.com/stock/news/2787962/pfizer-discusses-drug-pricing-deal-metsera-buyout-dispute-on-q3-call

Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal - Metsera ( NASDAQ:MTSR ) , Novo Nordisk ( NYSE:NVO ) , Pfizer ( NYSE:PFE )

The Delaware Chancery Court denied Pfizer Inc.'s ( NYSE:PFE ) request for a temporary restraining order to prevent Metsera, Inc. ( NASDAQ:MTSR ) from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk A/S ( NYSE:NVO ) .

https://www.benzinga.com/m-a/25/11/48693778/pfizer-to-raise-metsera-bid-after-court-denies-attempt-to-block-rival-deal

Novo, Pfizer Battling Over Future Of Weight-Loss Drugs - Viking Already Owns It - Metsera ( NASDAQ:MTSR ) , Novo Nordisk ( NYSE:NVO ) , Pfizer ( NYSE:PFE )

Pfizer Inc's ( NYSE:PFE ) lawsuit. Novo Nordisk A/S' ( NYSE:NVO ) counterbid. And in the middle of it all - a quiet $45 million position that might turn into Andreas Halvorsen's next masterstroke. After years of fighting from the sidelines of the Ozempic boom, Pfizer is finally throwing punches.

https://www.benzinga.com/m-a/25/11/48634701/novo-pfizer-are-battling-to-buy-the-future-of-weight-loss-but-viking-already-owns-it

Trending Today

ZCash ($ZEC) Crypto Forecast: Up 13.6% Today

Monero ($XMR) Crypto Forecast: Up 5.2% Today

Upwork Inc. ($UPWK) Stock Forecast: Down 6.7% Today

Affirm Holdings Inc. ($AFRM) Stock Forecast: Up 5.0% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.5% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 7.6% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Up 6.0% Today

Albemarle Corporation ($ALB) Stock Forecast: Up 6.8% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Down 5.0% Today

Amdocs Limited ($DOX) Stock Forecast: Down 9.1% Today

Pfizer Inc. Price History

30.09.2025 - PFE Stock was up 0.5%

• Despite the bearish options activity detected by investors, Pfizer's stock saw a significant bullish movement, indicating a potential divergence between options trading sentiment and actual market performance.
• Criticism of Plug Power and positive outlook on Sempra did not directly impact Pfizer's bullish movement, suggesting that company-specific news may not have been the primary driver of today's market activity.
• The -1.09% drop in Pfizer's stock price in the latest trading session may have been overshadowed by broader market gains, leading to the overall bullish movement observed.
• With Pfizer's Q3 earnings expected to decline, the market's bullish response today could be attributed to other factors such as positive industry developments or investor sentiment shifting towards pharmaceutical stocks in general.

15.06.2025 - PFE Stock was down 2.4%

• Pfizer's stock price declined by 1.17% as the market rallied, indicating a bearish trend for the company.
• The announcement of a $1 billion net IRA impact in 2025 due to Medicare Part D changes likely contributed to investor concerns and the negative market reaction.
• The FDA's acceptance of GlaxoSmithKline's filing for expanded use of RSV vaccine in younger adults may have shifted some focus away from Pfizer, impacting its stock performance.
• Moderna's stock surging after receiving full FDA approval for its COVID-19 vaccine in pediatric patients could have also diverted investor attention from Pfizer, potentially leading to the bearish movement in Pfizer's stock price.

05.07.2025 - PFE Stock was up 5.0%

• Strong bullish movement attributed to impressive Q2 earnings, beating estimates with significant growth in earnings and revenues.
• Rising sales in oncology drugs like Vyndaqel, Comirnaty, and Paxlovid, as well as cost-cutting measures expected to save billions by 2027, fueled the positive market response.
• Optimism further boosted by the company's raised 2025 EPS guidance and expectations of continued strength in key products like Vyndaqel and Padcev.
• President Trump's ultimatum to lower drug prices may have influenced the overall positive sentiment, potentially benefiting companies like Pfizer in the long run.

05.07.2025 - PFE Stock was up 5.3%

• Pfizer reported better-than-expected Q2 earnings, with EPS beating consensus and sales rising by 10% year-over-year, driven by key products like Vyndaqel, Comirnaty, and Paxlovid.
• The company raised its 2025 EPS guidance and announced cost-cutting measures expected to save $7.7 billion by the end of 2027, which boosted investor confidence in the stock.
• Despite facing declines in some products like Eliquis, Ibrance, and Prevnar, Pfizer's overall performance and future outlook seem promising, leading to the bullish market movement.
• The negative news about Trump issuing an ultimatum to pharmaceutical companies to lower drug prices did not significantly impact Pfizer's stock, as the positive earnings report overshadowed external pressures.

30.08.2025 - PFE Stock was up 5.7%

• Pfizer's stock saw a surge following reports of an agreement with President Trump to lower drug prices voluntarily, showcasing a positive impact on the company's reputation and potential market growth.
• Despite legal challenges related to Depo-Provera brain tumor claims, the news did not notably affect the stock's performance today, with investors focusing on the favorable developments.
• The acquisition of Metsera by Pfizer for next-generation weight loss drugs is viewed as a strategic maneuver that could enhance innovation and research expenditure, bolstering the optimistic sentiment.
• Despite a recent stock price decline, today's bullish movement demonstrates resilience and investor confidence in Pfizer's future prospects, especially with the spotlight on a potential drug-pricing arrangement.

04.10.2025 - PFE Stock was up 0.2%

• Pfizer's stock showed strong bullish movement today after surpassing earnings and revenue estimates for the third quarter of 2025, displaying robust financial performance.
• The market responded positively to Pfizer increasing its profit guidance despite a slight decline in sales, reflecting investor confidence in the company's ability to overcome obstacles and sustain profitability.
• The updated proposal from Novo Nordisk to acquire Metsera might have influenced market sentiment, potentially bolstering Pfizer's position in the pharmaceutical sector as competitors seek strategic acquisitions.
• Overall, Pfizer's strong performance in core drug sales and positive profit outlook in a challenging market environment likely contributed to the bullish movement in its stock price today.

10.10.2025 - PFE Stock was down 2.2%

• The bearish movement in Pfizer's stock could be attributed to the uncertainty surrounding the fierce bidding war with Novo Nordisk over the acquisition of Metsera, Inc., a significant deal worth $10 billion. The market might be reacting negatively to the potential financial implications and risks associated with this high-stakes competition.
• Additionally, Trump's Most Favored Nation (MFN) policy aimed at reducing U.S. drug prices could be adding pressure on Pfizer and other pharmaceutical companies, leading to concerns about future revenue streams and profitability.
• The court's decision to deny Pfizer's request for a temporary restraining order to block Novo Nordisk's bid for Metsera might have further fueled investor uncertainty and contributed to the bearish sentiment surrounding Pfizer's stock.
• Overall, the combination of the bidding war, drug pricing concerns, and legal setbacks could have collectively influenced the bearish market movement for Pfizer today. Investors are likely closely monitoring the developments in these ongoing battles and policy changes to assess the company's future performance.

01.09.2025 - PFE Stock was up 7.7%

• The stock of Pfizer witnessed a significant surge in the market today.
• An agreement on drug pricing with President Donald Trump has fueled this bullish movement, indicating promising prospects for the company's future revenue and competitive position.
• Investor confidence in Pfizer received a boost from this agreement, which also eased industry concerns regarding potential tariff impacts, resulting in a positive market trend.
• Positive remarks from Mark Cuban regarding Trump's online pharmacy initiative and its potential enhancements may have contributed to the optimistic outlook on Pfizer's stock.
• The collaboration between Pfizer and the U.S. government to lower drug prices has not only enhanced the company's stock performance but has also underscored its dedication to addressing healthcare affordability challenges.

01.09.2025 - PFE Stock was up 7.4%

• Pfizer's stock experienced a bullish movement following reports of an agreement with President Donald Trump to lower drug prices. This news likely boosted investor confidence in the company's future prospects.
• The deal with Trump and the positive response from the pharmaceutical industry regarding Pfizer's tariff situation provided a favorable outlook for the company, leading to increased buying interest in the stock.
• Mark Cuban's assessment of Trump's online drug store venture and the upcoming court hearing over Depo-Provera brain tumor claims may have added some volatility to Pfizer's stock but did not deter the overall bullish sentiment driven by the drug pricing deal announcement.
• Overall, the market movement of Pfizer today can be attributed to a combination of positive news related to drug pricing agreements and potential challenges the company may face in the legal arena.

01.09.2025 - PFE Stock was up 7.5%

• Pfizer's stock surged due to a significant agreement with the administration to reduce prescription drug prices, fostering optimism in the pharmaceutical sector.
• Granting Pfizer a three-year exemption from pharmaceutical tariffs by the administration enabled the company to provide medications at reduced prices, bolstering investor confidence.
• The agreement not only benefited Pfizer but also had broader implications for companies such as CVS Health, Eli Lilly, and UnitedHealth Group.
• Market response indicates that Pfizer's strategic decisions and alignment with government policies have positioned it favorably, leading to a bullish trend in its stock price.

08.06.2025 - PFE Stock was up 2.2%

• Pfizer's strong bullish momentum is linked to its consistent trading performance above the 50-day average, reflecting robust positive momentum amid challenges like declines in COVID revenues and patent-related risks.
• The recent decision by the FDA chief to restrict COVID-19 vaccine approval to seniors and high-risk groups is thought to have positively influenced Pfizer's stock, considering its significant role in the vaccine market.
• Moderna's stock surge subsequent to the CDC's expanded RSV vaccine recommendations might have also played a part in the positive outlook for the pharmaceutical industry, indirectly benefiting Pfizer.
• The decrease in sales of legacy drugs for Bristol Myers (BMY) potentially underscored Pfizer's resilience and dedication to innovative products, potentially drawing investors' attention to Pfizer's stock.

25.07.2025 - PFE Stock was down 2.1%

• Pfizer's (PFE) stock price sharply declined today, despite a recent uptrend in the past month, potentially indicating profit-taking or shifting market sentiment.
• Despite reports of major investors taking bullish positions on Pfizer, the market movement appeared bearish today. It's crucial to recognize that multiple factors beyond investor sentiment can influence market dynamics.
• The bearish trend could be linked to overall market movements, industry-specific updates, or internal developments impacting Pfizer's stock negatively.
• Investors are advised to monitor forthcoming announcements or updates regarding Pfizer to gain insights into the causes behind today's market downturn.